文献速递心力衰竭与心肌病肺血管病与心包/心肌炎

射血分数保留与降低心衰中肺动脉高压的差异

Pulmonary Hypertension in HFpEF and HFrEF: JACC Review Topic of the Week.
PubMed 文献 · J Am Coll Cardiol · 2020-01-01

本综述聚焦于左心疾病相关肺动脉高压(第2组)在射血分数保留心衰(HFpEF)与射血分数降低心衰(HFrEF)中的机制与临床表型差异。尽管两者肺压升高均与左房压增高相关,但病因、合并症及心脏重构不同,提示肺动脉高压发生存在差异。认识这些差异有助于探索个体化治疗。

要点

  • HFpEF与HFrEF所致肺动脉高压均与左房压升高相关。
  • 两综合征在病因、合并症和心脏重构上存在明显差异。
  • 血流动力学相似但肺动脉高压发生机制可能不同。

核心结论

  • HFpEF与HFrEF相关肺动脉高压虽血流动力学相似,但驱动机制、病理生理和临床表型可能存在差异。

研究设计与样本

  • 综述类文章,检索范围未明确报告。

主要发现

  • HFpEF与HFrEF的主要差异包括潜在病因、相关合并症和心脏重构。
  • 尽管血流动力学特征相似,肺动脉高压的发展可能存在差异。

临床怎么用

  • 应关注HFpEF与HFrEF相关肺动脉高压的差异,以寻求个体化且及时的治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pulmonary hypertension (PH) associated with left heart disease, or Group 2 PH, includes heart failure, valvular heart diseases, and congenital heart diseases. Although it is axiomatic that in PH due to heart failure the increase in pulmonary pressure is directly related to an enhanced left atrial pressure, which is common to both heart failure with preserved ejection fraction (HFpEF) and heart failure with reduced ejection fraction (HFrEF), there has been limited attention over the years on the potential differences in terms of driving mechanisms, pathophysiology, and clinical phenotypes. Major differences between HFpEF and HFrEF are the underlying causes, associated comorbidities, and cardiac remodeling. This suggests that despite similar hemodynamic profiles, there may be some disparities in PH development. A focused knowledge on the differences between the 2 syndromes has relevant implications to seek new, personalized, and timely treatments for Group 2 PH. The purpose of the present review is to highlight the mechanisms and clinical phenotypes of PH in HFpEF and HFrEF.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Guazzi M, Ghio S, Adir Y, et al. Pulmonary Hypertension in HFpEF and HFrEF: JACC Review Topic of the Week. J Am Coll Cardiol. 2020. PMID: 32854845. doi:10.1016/j.jacc.2020.06.069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。